This study reveals that N-acetylmannosamine may enhance sialic acid levels in sialin-deficient models, but does not completely restore ganglioside sialylation.
Lysosomal free sialic acid storage disorder (FSASD) is an ultra-rare neurodegenerative condition caused by mutations in SLC17A5 , which encodes the lysosomal sialic acid exporter, sialin. Deficiency of sialin leads to lysosomal accumulation of unconjugated ("free") sialic acid. This study investigated the ability of N-acetylmannosamine (ManNAc), a precursor of sialic acid, to rescue glycosphingolipid (GSL) sialylation in a SLC17A5-deficient HEK-293T model system. Our findings reveal that while ManNAc supplementation may enhance sialic acid biosynthesis, it does not fully restore ganglioside sialylation to wild-type levels, highlighting the essential role of lysosomal sialic acid recycling in maintaining GSL sialylation homeostasis.
No takes yet. Share an insight, caveat, or question.
Sabir et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: